908 Devices (MASS) Competitors

Cytek Biosciences (NASDAQ:CTKB) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, community ranking, institutional ownership, analyst recommendations and media sentiment.

Is CTKB or MASS more profitable?

Cytek Biosciences has a net margin of -5.05% compared to 908 Devices' net margin of -109.11%. Cytek Biosciences' return on equity of -2.58% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-5.05%	-2.58%	-2.05%
908 Devices	-109.11%	-24.60%	-19.23%

Does the media favor CTKB or MASS?

In the previous week, 908 Devices had 4 more articles in the media than Cytek Biosciences. MarketBeat recorded 8 mentions for 908 Devices and 4 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 1.17 beat 908 Devices' score of 0.25 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
908 Devices	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate CTKB or MASS?

Cytek Biosciences presently has a consensus target price of $6.42, suggesting a potential upside of 72.49%. 908 Devices has a consensus target price of $5.33, suggesting a potential upside of 19.85%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
908 Devices	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community prefer CTKB or MASS?

Cytek Biosciences received 3 more outperform votes than 908 Devices when rated by MarketBeat users. However, 50.00% of users gave 908 Devices an outperform vote while only 45.83% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
Cytek Biosciences	Outperform Votes 22 45.83%	Underperform Votes 26 54.17%
908 Devices	Outperform Votes 19 50.00%	Underperform Votes 19 50.00%

Which has preferable earnings & valuation, CTKB or MASS?

Cytek Biosciences has higher revenue and earnings than 908 Devices. Cytek Biosciences is trading at a lower price-to-earnings ratio than 908 Devices, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$200.45M	2.38	-$12.15M	-$0.05	-74.40
908 Devices	$59.63M	2.64	-$36.40M	-$2.10	-2.12

Do institutionals and insiders believe in CTKB or MASS?

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 88.1% of 908 Devices shares are owned by institutional investors. 9.6% of Cytek Biosciences shares are owned by company insiders. Comparatively, 27.7% of 908 Devices shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has more risk and volatility, CTKB or MASS?

Cytek Biosciences has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Summary

Cytek Biosciences beats 908 Devices on 10 of the 17 factors compared between the two stocks.